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Abstract
Proteome studies contribute markedly to our understanding of parasite biology, host-parasite interactions, and mechanisms
of drug action. For most antimalarial drugs neither mode of action nor mechanisms of resistance development are fully
elucidated although this would be important prerequisites for successfully developing urgently required novel antimalarials.
Here, weestablisha large-scale quantitative proteomicapproachtoexamine protein expressionchangesintrophozoitestages
of the malarial parasite Plasmodium falciparum following chloroquine and artemisinin treatment. For this purpose SIL (stable
isotope labeling) using
14N-isoleucine and
13C6,
15N1-isoleucine was optimized to obtain 99% atomic percent enrichment.
Proteome fractionation with anion exchange chromatography was used to reduce sample complexity and increase
quantitative coverage of protein expression. Tryptic peptides of subfractions were subjected to SCX/RP separation, measured
by LC-MS/MS and quantified using the novel software tool Census. In drug treated parasites, we identified a total number of
1,253 proteins, thus increasing the overall number of proteins identified in the trophozoite stage by 30%. A relative
quantification was obtained for more than 800 proteins. Under artemisinin and chloroquine treatment 41 and 38 proteins
respectively were upregulated (.1.5) whereas 14 and 8 proteins were down-regulated (,0.5). Apart from specifically
regulated proteins we also identified sets of proteins which were regulated as a general response to drug treatment. The
proteomic data was confirmed by Western blotting. The methodology described here allows for the efficient large-scale
differentialproteomeanalysisofP.falciparumtostudytheresponsetodrugtreatmentorenvironmentalchanges.Only100 mg
of protein is required for the analysis suggesting that the method can also be transferred to other apicomplexan parasites.
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Introduction
The parasitic protozoon Plasmodium falciparum is responsible for
approximately 500 million cases of malaria and one million deaths
from malaria each year. Recent anti-mosquito measures and new
artemisinin-containing treatments prompted calls for global
malaria eradication. Novel drugs, vaccines, and insecticides, as
well as deeper insights into parasite biology, human immunity, and
vector behavior are essential to support these efforts [1]. Proteome
studies contribute markedly to our understanding of parasite
biology, host-parasite interactions, and mechanisms of drug action
[2]. Respective analyses identifying proteins of different stages of
malarial parasites have been carried out in our and other
laboratories [3,4]. Mass spectrometric (MS) methods like the
Multidimensional Protein Identification Technology (MudPIT)
were developed to enable large scale identification of proteins. In a
typical MudPIT analysis an unfractionated protein mixture is
digested to peptides, separated by biphasic liquid chromatography
(SCX-RP-LC), and analyzed online by tandem mass spectrometry.
Such approaches can include either in vitro or in vivo isotope tagging
of amino acids which enables pair-wise comparison of protein
expression patterns [5,6]. Resulting data provide important
insights into molecular mechanisms in cells including stress
response and mechanisms of drug action and resistance.
Stable isotope labeling with heavy amino acids is a well
established technique for protein labeling. It uses metabolic
labeling, where the respective isotope-labeled amino acid is
translationally inserted into proteins and no chemical labeling
and purification steps after labeling are needed. Although stable
isotope labeling of Plasmodium is complicated by the required use of
red blood cell cultures, the application of SIL was developed for P.
falciparum by Nirmalan et al. in 2004 in combination with 2DE [7].
Due to resembling physicochemical properties the isotope labeled
proteins or peptides display similar separation characteristics in
electrophoresis or chromatography. In liquid-chromatography
separation prior to MS the labeled and unlabeled peptides co-
elute from the chromatographic column. In the MS they can be
resolved, measured, and compared in the same scans. The amino
acid best suited for labeling proteins of malaria parasites is
isoleucine [4]. It is not synthesized but taken up efficiently by
Plasmodium and gives–
13C6
15N1 minus
12C6
14N1–a spectral sepa-
ration of 7.017159 Da. Of all P. falciparum proteins more than 99%
have isoleucine containing peptides and thus can be theoretically
covered in this approach (plasmodb.org).
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4098In the present study we aimed at developing a large-scale
quantitative proteomic approach in malarial parasites as an
efficient method for studying cellular response to e.g. drug pressure
or environmental changes. For this purpose we employed
isoleucine-based SILAC in combination with proteome fraction-
ation via anion exchange chromatography, SCX/RP for peptide
separation, LC-MS/MS analysis, and quantification using the
novel software tool Census. This strategy represents a general
approach that can be used to study the mechanism of action for
drug treatment of pathogens.
Results
Within the framework of this study we established the first large
scale comparative proteomics analysis for Plasmodium falciparum.T o
optimize labeling efficiency with
13C6
15N1 isoleucine three
complete cycles of growth (72 hours) were carried out leading to
an average labeling efficiency of 99%. The use of high mass
accuracy instruments and new software tools maximized the
number of protein identifications, while at the same time enabling
quantitative comparisons.
Protein Identification
The measurement of tryptic digests of P. falciparum trophozoite
stages by MudPIT led to the identification of 1,253 parasite proteins
(or 6,318 peptides) in total. The numbers of identifications and
regulatedproteinsforthedrug-treatedsamplesareshowninTable1.
The supplementary Table S1 contains all identifications from
trophozoite extracts produced in this study. The data obtained
allowed for a significant enhancement of protein identification
numbers for this parasite stage compared to previous studies [3,4].
This improvement was largely supported by a prefractionation
step on the protein level. Fractionation of the soluble protein
extract was performed on weak anion exchanger chromatographic
columns to obtain three different protein fractions. These fractions
plus the insoluble 100.000 g protein pellet constitute the four
protein fractions used in our MS experiments. SDS-PAGE of the
obtained fractions indicates that separation into subfractions was
successful as the protein band patterns of the fractions differ
considerably (Figure 1a).
To define the potential benefit of our fractionation procedure,
we compared ID numbers of MudPIT runs of the unfractionated
soluble sample to the fractionated soluble sample (three fractions).
Through fractionation the overall number of IDs increased by
about 30% as well as the quantification of all peptides identified.
Figure 1b summarizes the number of protein identifications in
non-fractionated and fractionated samples. Of all Plasmodium
predicted proteins, all except one contain at least one isoleucine
and thus could theoretically be quantified by an approach using
labeled isoleucine. In order to assess the benefit of the presented experimental
setup, we submitted the mass spectrometric datasets of a previous
study conducted in our lab [3] and the present study to the same
search and filtering parameters for a comparable amount of
MudPIT runs. We detected an increase in the number of protein
identifications of 34% (data not shown). Thus, our study adds 384
proteins to the erythrocytic stage that had not been identified
previously [3,4], which represents a further step towards the
completion of the Plasmodium falciparum proteome in the erythro-
cytic stages. The increase of identifications through fractionation is
displayed in the Venn diagram (Figure 1c). Proteins that are
exclusively found in the respective fractions are shown.
The distribution of the functional profiles of the identified
proteins is summarized in Figure 2. Large parts of the measured
proteome contribute to important cellular functions including
Table 1. Total number of proteins identified in trophozoite
stages of Plasmodium falciparum after drug treatment.
Furthermore the numbers of regulated proteins are given.
Chloroquine Artemisinin
Total Protein Identifications with Isoleucine 1211 1165
Overlap with Control 889 814
Upregulated (.1.5) 41 38
Down Regulated (,0.5) 14 8
doi:10.1371/journal.pone.0004098.t001
Figure 1. Quantification improvement by fractionation of cell
extracts. A: Fractionation of P. falciparum trophozoite extracts by
centrifugation and low-strength anion exchange chromatography. F1 to
F3 are fractions derived by separation of the 100.000 g supernatant on
low-strength anion exchanger chromatography. F1 (flowthrough); F2
(200 mM NaCl eluate); F3 (500 mM eluate); F4 (100.000 g pellet). The
band pattern shows a fractionation into different subproteomes. B:
Venn diagram comparing numbers of protein identifications of a
previous MudPIT study by Florens et al. [3] and our current study, where
prefractionation was applied. C: Venn diagram summarizing numbers of
protein identifications per fraction and overlaps with other fractions.
doi:10.1371/journal.pone.0004098.g001
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communication, transport, and biosynthesis. As deducible from a
ranked list of all P. falciparum genes on PlasmoDB, many of these
identified proteins represent important antimalarial drug targets.
The opportunity to study these proteins quantitatively and
differentially in a large scale approach will support future drug
development strategies. In accordance with the genome annota-
tions, a considerable percentage of the identified proteins are of
unknown function. The methodology described here will facilitate
more detailed studies.
Relative quantification of isoleucine containing proteins
Relative quantification of isoleucine containing peptides was
performed using the software tool Census [8]. We were able to
quantify an average of 75% of all identified isoleucine-containing
peptides for each dataset. In the chloroquine treated cells we
relatively quantified 889 proteins, in the artemisinin treated cells
814. Figure 3 displays the count of peptides per quantified protein,
showing that for quantification of 83% of the proteins at least two
peptides were used. The average number of measured peptides per
identified protein ranged from ,5.8 to ,6.2 in our experiments.
A validation of the quantification data was performed for five
proteins for which antibodies were available. The immunoblots for
the selected proteins are shown in Figure 4. The parasite proteins
thioredoxin reductase (TrxR), glutathione reductase (GR), and
thioredoxin (Trx) displayed no significant regulation in the mass
spectrometry experiments (Table S1), which was confirmed in the
immunoblots. For EBA-75 (erythrocyte binding antigen) we saw
Figure 2. Functional classification of identified proteins. Identified proteins were classified using go annotations downloaded from PlasmoDB
(www.plasmodb.org) and simplifying it with go-slim. The classification shows a widespread distribution of the identified proteins in metabolism.
doi:10.1371/journal.pone.0004098.g002
Figure 3. Number of peptides per protein used for quantification. Number of identified peptides with at least one isoleucine in their
sequence per protein that have been quantified using Census against their incidence.
doi:10.1371/journal.pone.0004098.g003
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artemisinin SIL quantification as well as 1.57 and 1.40 in the
immunoblot validation, respectively. Also histone H3, which was
quantified in the SIL-MS analysis with 7 (CQ) and 8 (Arte)
peptides as upregulated by 1.26 (CQ) and 1.96 (Arte), showed a
similar regulation in the immunoblots with values of 1.15 (CQ)
and 2.06 (Arte). These experiments prove that the quantifications
determined by SIL deliver essentially the same results as the
immunoblots. Thus our SIL approach is capable of presenting
valuable protein profiling data for more than 800 proteins per
comparison.
Regulation of proteins under drug pressure
Our treatment regimen was to expose the cells in the early
trophozoite stage to double IC50–values of the respective drug for
twelve hours. An analysis of cell viability after certain time points
showed that treated cells were fully viable and proved full
reproductive abilities after treatment (see Methods for details).
This information is important to verify that the observed proteome
changes represent a specific drug response rather than changes
induced by cell death.
The SIL quantification data show that a fraction of proteins was
significantly regulated after treatment with chloroquine or
artemisinin under chosen conditions (Table S1 and Table 2).
When using a value of 0.5 for down regulation and of 1.5 for
upregulation, we observed the following numbers. From 889
quantified proteins in chloroquine treated cells 41 were upregu-
lated and 14 down regulated. In artemisinin treated cells, we
observed 38 upregulated and 8 down regulated proteins from 804
quantified. These numbers, of course, vary with different set-offs
for regulation factors used. Here we chose stringent factors that
produce a manageable number of proteins.
Table 2 contains selected proteins regulated only under one
treatment regimen (chloroquine or artemisinin) or equally
regulated under both treatments. Proteins regulated only after
chloroquine treatment include for example the conserved protein
PFC0135c and the DNA replication licensing factor mcm5, which
were both upregulated by more than fivefold and quantified with
five or four peptides, respectively. These proteins were not
upregulated under artemisinin treatment; rather, PFC0135C was
markedly down regulated (0.28). Overall, sixteen proteins (with six
hypothetical and conserved proteins) were specifically upregulated
in chloroquine treated cells; six proteins were specifically down
regulated. These include four hypothetical proteins and the basic
transcription factor 3b.
Proteins specifically upregulated (.1.5) in artemisinin treated
cells include 18 proteins (with seven hypothetical proteins). These
comprise e.g. three proteasomal subunits, a thymidylate kinase and
a long-chain fatty acid CoA ligase. Artemisinin treatment led to a
reduced expression of five proteins, which include a hypothetical
and a conserved protein, a eukaryotic translation initiation factor,
a putative glutamate dehydrogenase and the putative co-
chaperone GrpE. Interestingly, the conserved protein PFC0135c
was down regulated after artemisinin treatment by a factor of 0.28,
whereas it was upregulated under chloroquine pressure more than
fivefold, as described above.
Table 2 furthermore contains proteins which were up- or down
regulated similarly under both treatment regimens. Twenty-six
proteins were upregulated under both drugs (.1.3). These
proteins include histones H3 and H4, the lipoamide dehydroge-
nase, a steroid dehydrogenase and a multidrug resistance protein.
Again, a huge proportion of proteins (10 out of 26) has not been
assigned a function yet. Twenty proteins were down regulated by a
factor of at least 0.75 in both samples. To this group eleven
hypothetical proteins are counted as well as a putative calcyclin
binding protein, a GTP cyclohydrolase I, the ribosomal protein
S26e or a putative ubiquitin-conjugating enzyme.
750 proteins were observed in both studies (CQ and arte) and
680 of these showed the same trend (less than 20% difference
among the two ratios) in both samples. The rest of the proteins
displaying different regulations under artemisinin and chloroquine
treatment, as summarized in Table 2, are of special interest as they
should represent a drug specific response.
Discussion
The first large-scale comparative study on the effects of
treatment with the antimalarial drugs artemisinin and chloroquine
on the proteome of P. falciparum was performed using metabolic
labeling followed by identification and quantification with
MudPIT LC-MS. The strategy of labeling proteins with stable
isotope labeled isoleucine as described by Nirmalan et al. [7] for
2DE was used to create internal standards. By replacing the 2DE
procedure with high-resolution LC-MS, where separation, iden-
tification and quantification are performed in parallel, we were
able to identify and quantify a significantly larger number of
proteins. To establish the method described here, the efficiency of
labeling parasite proteins with
13C6
15N1 isoleucine in cell culture
was optimized until it reached 99%. Different methods were
compared to fractionate cell extracts into sub-proteomes, including
weak anion exchange chromatography with salt elution or pH
elution and a sequential ammonium sulfate precipitation. As
determined by direct comparison of fractionated and unfraction-
ated samples, the fractionation procedure described in the
methods section enhanced the number of identified proteins by
30%. Combining sample fractionation with the use of a high mass
accuracy Orbitrap enabled the identification of an additional 384
proteins that had not been determined previously in proteome
analyses. More than 800 proteins could be quantitatively
compared between drug treated and untreated samples. Only
100 mg of protein was required for each LC-MS analysis of
Plasmodia; thus the method is likely to be applicable for studying
Figure 4. Validation of SILAC data by immunoblotting. The
following polyclonal antibodies were used: rabbit-anti-PfTrxR (thior-
edoxin reductase), rabbit-anti-PfGST (glutathione S-transferase), rabbit-
anti-PfGR (glutathione reductase) (available in the Becker Lab), rabbit-
anti-Histone H3 (Abcam, Cambridge, UK), rabbit-anti-PfEBA (Erythrocyte
Binding Antigen) (MRA-2 by MR4) at appropriate dilutions 1:1,000–5,000
and peroxidase-conjugated anti-rabbit antibody (Dianova, Hamburg,
Germany, anti-IgG, 1:50,000–100,000). Visualization was performed by
enhanced chemiluminescence (ECL, SuperSignal West Femto Maximum
Sensitivity Substrate, Pierce Biotechnology, Rockford, IL, USA). Densito-
metric quantification was performed using the Quantity One software
(BioRad) by quantitating band volumina (trace intensity6mm
2) of each
sample and comparing treated and control band volumina.
doi:10.1371/journal.pone.0004098.g004
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Protein ID Description RATIO Arte Peptides Arte RATIO CQ Peptides CQ
MAL13P1.307 hypothetical protein 1.11 2 3.40 3
MAL13P1.92 40S ribosomal protein S15 0.72 1 1.78 2
PF07_0073 seryl-tRNA synthetase 0.97 10 1.51 7
PF11_0348 hypothetical protein 1.06 1 1.86 2
PF13_0198 reticulocyte binding protein 2 homolog a 1.24 1 1.65 1
PFC0135c conserved protein 0.28 5 5.11 5
PFC0365w conserved protein 1.02 3 1.55 4
PFC0730w conserved protein 0.65 2 1.61 2
PFF0335c hypothetical protein 0.99 3 1.61 2
PFF0615c P. falciparum membrane protein pf12 precursor 0.74 2 1.66 2
PFI0235w replication factor A-related protein 1.14 3 1.50 3
PFI0290c beta subunit of coatomer complex 1.02 6 1.51 6
PFI1175c RNA-binding protein 1.21 1 1.52 1
PFL0580w DNA replication licensing factor mcm5 1.26 3 5.76 4
PFL1420w macrophage migration inhibitory factor homolog 1.22 3 1.74 2
PFL1620w asparagine/aspartate rich protein 1.28 2 1.65 3
MAL13P1.343 proteasome regulatory subunit 1.63 2 0.94 1
MAL8P1.127 hypothetical protein 1.52 3 0.96 5
PF07_0040 lysophospholipase-like protein 1.80 3 1.28 4
PF08_0121 peptidyl-prolyl cis-trans isomerase precursor 1.90 3 1.11 1
PF10_0043 ribosomal protein L13 2.02 1 0.83 8
PF10_0111 20S proteasome beta subunit 2.95 4 1.02 4
PF11_0053 PfSNF2L 1.53 8 1.12 11
PF11_0384 hypothetical protein 1.60 1 1.29 1
PF13_0199 hypothetical protein 9.62 1 0.81 1
PF14_0242 arginine n-methyltransferase 2.09 2 0.89 2
PFB0835c hypothetical protein 3.40 2 0.84 1
PFC0720w hypothetical protein 1.50 4 1.11 2
PFC0915w ATP-dependent RNA helicase 1.69 1 0.98 2
PFE0915c proteasome subunit beta type 1 1.69 4 1.12 4
PFE1250w long-chain fatty acid CoA ligase 3.11 2 0.84 3
PFF0445w hypothetical protein 2.52 2 0.89 3
PFF0885w 60S ribosomal protein L27a 1.82 8 1.05 6
PFL2390c hypothetical protein 1.86 3 1.17 3
PFL2465c thymidylate kinase 4.88 2 1.05 2
MAL7P1.38 regulator of chromosome condensation protein 1.49 4 2.28 4
PF11_0061 histone H4 2.34 8 2.56 12
PF11_0142 hypothetical protein, conserved 2.94 2 1.37 3
PF11_0424 hypothetical protein 1.45 1 1.56 1
PF13_0102 DNAJ-like Sec63 homologue 1.34 5 1.43 6
PF13_0224 60S ribosomal subunit protein L18 1.84 4 1.45 4
PF13_0252 nucleoside transporter 1 1.47 2 1.49 2
PF14_0215 hypothetical protein 8.46 1 1.59 3
PF14_0231 ribosomal protein L7a 1.31 5 1.48 4
PF14_0567 hypothetical protein 1.60 7 1.68 6
PFC0262c hypothetical protein, conserved 31.43 1 26.16 1
PFC0535w 60S ribosomal protein L26 1.86 1 1.33 1
PFC0900w T-complex protein 1 epsilon subunit 1.31 6 1.55 2
PFC0945w protein kinase 1.58 1 1.45 1
PFD0385w hypothetical protein 1.61 3 2.15 2
Drug Induced Proteome Changes
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of cell extracts is limited. The experimental setup (parasite stage,
drug dose, incubation time) was chosen on the basis of the
available literature indicating that both CQ and artemisinin do act
on the late ring/early trophozoite stages of the parasites [9,10,11]
on desired high protein yields and on pretesting of the drugs in our
laboratory.
Effects of chloroquine
Chloroquine has been the mainstay of malaria prophylaxis and
therapy for the last 50 years. Today, resistance to this affordable
drug constitutes a major problem in the fight against malaria in
most of the malaria endemic countries [12]. A range of possible
mechanisms of action has been proposed for CQ. This includes
interference with heme polymerization leading to the release of
Protein ID Description RATIO Arte Peptides Arte RATIO CQ Peptides CQ
PFD1035w steroid dehydrogenase kik-i 1.94 1 2.56 3
PFD1070w eukaryotic initiation factor 1.57 2 1.37 2
PFE0340c hypothetical protein, conserved 1.35 3 1.33 3
PFE1150w multidrug resistance protein 1.75 8 1.66 13
PFF0510w histone H3 1.96 8 1.33 2
PFF0920c hypothetical protein 3.07 1 3.00 1
PFI0975c hypothetical protein 2.75 2 3.18 1
PFL0300c phosphoesterase 1.89 2 1.69 2
PFL0720w hypothetical protein 1.45 1 1.38 1
PFL1500w Rab2 GTPase 1.92 1 1.96 1
PFL1550w lipoamide dehydrogenase 1.40 4 1.43 2
MAL8P1.82 hypothetical protein 1.09 2 0.35 1
PF10_0031 hypothetical protein 0.91 6 0.18 2
PF14_0241 basic transcription factor 3b 0.93 2 0.01 1
PFC0390w hypothetical protein, conserved 0.84 2 0.41 2
PFL1705w hypothetical protein 0.86 6 0.36 1
MAL7P1.81 eukaryotic translation initiation factor 3 subunit 0.22 5 0.94 2
PF08_0132 glutamate dehydrogenase 0.23 2 1.32 2
PF11_0258 co-chaperone GrpE 0.39 2 1.11 2
PF13_0072 hypothetical protein 0.15 1 0.82 1
PFC0135c conserved protein 0.28 5 5.11 5
PF07_0101 hypothetical protein 0.45 2 0.62 2
PF10_0170 hypothetical protein 0.67 2 0.53 2
PF11_0396 Protein phosphatase 2C 0.73 8 0.59 3
PF11_0433 hypothetical protein 0.63 3 0.59 1
PF13_0011 Plasmodium falciparum gamete antigen 27/25 0.46 3 0.24 2
PF14_0341 glucose-6-phosphate isomerase 0.73 6 0.69 7
PF14_0706 hypothetical protein 0.65 3 0.67 4
PFB0120w hypothetical protein 0.58 1 0.56 2
PFB0640c hypothetical protein 0.69 3 0.65 3
PFB0680w hypothetical protein 0.56 8 0.70 7
PFB0830w Ribosomal protein S26e 0.10 1 0.06 1
PFC1025w F49C12.11-like protein 0.71 3 0.65 2
PFD0800c hypothetical protein 0.70 1 0.66 1
PFD1130w hypothetical protein 0.72 1 0.68 1
PFE1350c ubiquitin-conjugating enzyme 0.72 1 0.66 3
PFF0860c histone H2a 0.73 5 0.74 4
PFF0880c hypothetical protein 0.70 5 0.67 7
PFL1155w GTP cyclohydrolase I 0.66 3 0.38 3
PFL1340c hypothetical protein 0.52 2 0.75 3
PFL1845c calcyclin binding protein 0.71 3 0.45 2
doi:10.1371/journal.pone.0004098.t002
Table 2. cont.
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interference with DNA excision repair [13]. More recently,
studying the effects of CQ on endocytosis of Plasmodium falciparum
revealed an inhibition of vesicle trafficking [14]. As reported by
Radfar et al., CQ furthermore mediates specific proteome
oxidative damage in the parasite [15]. As suggested by these
independent results, CQ may actually act on multiple molecular
targets in parallel, which could explain its extraordinary
effectiveness over a long period of time.
In our study, most proteins showing increases in expression are
localized to the nucleus or interact with chromosomes. Also proteins
involved in translation show obvious quantitative expression
changes. The amplitude of change remains low and variation in
specific functional cascades is difficult to characterize, as already
reported [16,17]. One of the largest hindrances to identifying
particular pathways affected by the drug is the high number of
hypothetical proteins that show changes. These proteins can
currently not be classified to a particular pathway, which will,
however, improve over time. In addition, our data is in accordance
with the observation of Gunasekera et al., who observed broad
mRNA expression changes in parasites treated with CQ [16,17].
These changes affected particularly ribosomal proteins, signaling
molecules, protein processing (heat shock proteins, proteasome
subunits, cyclophilin), as well as RNA metabolism (transcription
factors). There is a high degree of overlap between the functional
group of proteins in the transcriptome data and our proteome study,
however, the observed changes are less pronounced at the protein
level. A direct and quantitative comparison of the proteome and
transcriptome datasets has its limitations since parasite stages
employed, synchronicity, drug doses and exposure times varied
between the studies.
Effects of artemisinin
Over the last years artemisinin has become indispensable as an
alternative treatment of malaria as the CQ and the sulfadoxine/
pyrimethamine combination have become increasingly ineffective
[18]. As for the quinolines many hypotheses for the mechanism of
actionofartemisininhavebeenproposed[13,19].Akeyfeatureofall
artemisinins is the 1,2,4-trioxane structure with its endoperoxide,
which is essential for antimalarial activity. Active endoperoxides are
thought to interact with reduced hemin or other sources of ferrous
iron inside the parasite forming cytotoxic carbon-centered radical
intermediates. These intermediates can alkylate biomolecules like
lipids, heme and parasite enzymes including the ATP-dependent
Ca
2+ pump located on the endoplasmic reticulum, PfATP6.
Indeed, our data shows changes of the vacuolar ATP synthase;
subunits a and c (PF13_0130) display down regulation when the
parasite is treated with artemisinin. In addition, several processes
show slight upregulation under artemisinin when classifying the data
with GO annotations. This upregulation affects mainly nucleotide
and nucleic acid metabolism, transport and secretion as well as the
expected response to stimuli. One of the most important
observations is that the multidrug resistance gene was found to be
upregulated under CQand artemisininindicating that pfmdr1indeed
mediates resistance to a number of unrelated classes of agents [20].
Given the fact that approximately 40% of the identified and
regulated proteins are hypothetical proteins with unknown
functions in the parasite, the complexity of understanding the
biology of the malaria parasite is illustrated. Our study is the first
to dissect the protein expression response of chloroquine and
artemisinin treated Plasmodium falciparum cells on the proteome
level. We gain a list of sets of proteins specifically regulated under
each of the two drugs and sets of proteins similarly regulated.
Thus, our studies represent a basis for quantitative assessment of
protein changes induced by drug treatment. Using this method,
further investigations including different drug concentrations and
time points in combination with cell biological parameters will
allow to further understand mechanisms of action of single drugs
or drug combinations.
Methods
Cultivation of Plasmodium falciparum
The chloroquine sensitive P. falciparum strain 3D7 was grown in
continuousculture with slight modificationsasdescribed before [21].
The 3D7 strain is an established reference strain which had been
employed in most of the previous proteomic and transcriptomic
studies [9,10]. Briefly, parasites were maintained at 1–10%
parasitaemia and 3.3% haematocrit in RPMI 1640 culture medium
supplemented with A+ erythrocytes, 4% A+ human serum, 0.2%
lipid-richbovine serum albumin(Albumax), 0.16% glucose, 0.2 mM
hypoxanthine, 2.1 mM L-glutamine, and 22 mg/ml gentamycin.
Cultures were kept at 37uC, 3% O2,3 %C O 2 and 94% N2.
Synchronization of parasites in culture to ring stages was carried out
by repetitive treatment with 5% (w/v) sorbitol. Parasite growth and
parasitaemia were monitored by assessing Giemsa-stained blood
smears under the microscope. For determining IC50 and IC90 values
on the parasites the semi-automated microdilution technique based
on
3H-hypoxanthine incorporation was applied. For immunoblot-
ting analyses we prepared biological replicates without SILAC and
treated cells equally as in the SILAC experiment.
Heavy isotope labeling of P. falciparum proteins
For the drug exposure and heavyisotope labeling, specialized cell
culture conditions were applied. For this purpose we combined the
procedures published by Nirmalan et al., 2004 [7]and Koncarevic et
al., 2007 [21]. In contrast to standard conditions, parasites were
kept in the absence of human serum, which was replaced by
Albumax only. For heavy isotope labeling studies, custom RPMI-
1640 medium devoid of isoleucine was supplemented with
13C6,
15N1-isoleucine ($98% isotopic purity; Cambridge Isotope
Laboratories, Andover, MA, USA) to yield 7 Da mass shifts per
isoleucine in a peptide. Synchronized cultures were preincubated
for 24 h in isoleucine free medium before 0.38 mM heavy
(
13C6,
15N1) isoleucine (52.7 mg/ml) or light isoleucine (50 mg/ml)
was added to the parallel cultures. Isoleucine incorporation was
applied forthreecomplete lifecycles(3648 h)beforeadditionofthe
drugs. Blood stage cultures with a parasitemia of 8–10% at the late
ring/early trophozoite stage (24–28 h post infection) were incubat-
ed with chloroquine (CQ) or artemisinin (Arte) (26IC50
values=17 nM for CQ and 35 nM for Arte, determined 72 hrs
after addition of a drug which is not removed from the cell culture)
or the used solvent (RPMI-1640 medium or DMSO) for control
cultures. This experimental setup was based (a) on pretesting of
stage specificity and drug concentrations in our lab (b) on the fact
that it was desirable to harvest mature trophozoites in order to
obtain enough protein for the proteome analyses, and (c) on the
available literature which indicates that maximum effects of the two
drugs occurred at the late ring and early trophozoite stage, which
corresponds to the time at which the most rapid increases in
synthetic and glycolytic activities occur. Mature schizonts and
young rings are less affected by the antimalarial drugs [9,10]. This
data was recently substantiated by Maerki et al. [11] who confirmed
in their experiments that trophozoites were more susceptible to CQ
than rings or schizonts and that also for artemisinin good effects on
trophozoites were determined after 12 h.
For each drug, four samples were run in parallel: labeled
control, unlabeled control, labeled sample, and unlabeled sample.
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trophozoite/schizont stage and were harvested in parallel with the
controls. The window of the sorbitol-induced synchrony (.90%)
at which the trophozoites were harvested was approximately
5 hours. This window was achieved by repetitive sorbitol-induced
synchronizations (48 h, 96 h, 144 h, and 192, and 198 h before
the ring stage parasites that were later used for the experiment
were obtained). Since no reinvasion step was present during drug
exposure, the incubation time was rather short and the drug
concentrations were rather low (26IC50) the parasitemia did not
change within the 12 hours after drug treatment.
Parasite viability after drug treatment
Acontrolexperimentwasconductedinordertoassesstheviability
of the parasites after drug exposure. Parasites (6.4% parasitemia)
were exposed to the drugs as described above. After 12 h the drugs
were removed by changing the medium and washing the cells once
in medium. Cultures were then maintained under normal growth
conditions. The next schizogony took place simultaneously in the
three cultures resulting in 11.6% parasitemia with 5.4% residual
schizonts (CQ), in 11.6% parasitemia with 5.1% schizonts (Arte) and
in11.7%parasitemiawith 5.0%schizonts at thegivenwindow of the
sorbitol-induced synchrony.Inspiteofsimilar growthbehavior,drug
treated schizonts appeared slightly denser under the light micro-
scope. Cultures were then splitted (1:5 dilution to reduce the high
parasitemia) and incubated further. 17 h after peak schizogony
parasitemias of 6.3% rings (CQ), 6.4% rings (Arte) and 6.4%
(control) were determined.
The data indicates that–as intended-the drug treatment protocol
applied in our study did only slightly affect the parasites and did not
lead to major growth retardation or cell death. Treated and
untreated parasites differed by less than 1 hour in their develop-
mental stage. In fact, the aim inour study was to distinguish between
the changes from halted growth and the direct effect of drug
treatment using two drugs that are known to act on trophozoites.
The protein expression changesobserved under both drugsare likely
toreveal thechangesobservedfromhalted development whereas the
differences are related to the specific action of each drug. By using
this method, further investigations using different drug concentra-
tions and time points in combination with cell biological parameters
will allow a better understanding of mechanisms of action of single
drugs or drug combinations.
Preparation of parasite extracts
Thepreparationofparasite extractsfollowedestablishedprotocols
[21]. Briefly, parasites were isolated by lysing the red blood cell in
saponin containing buffer (7 mM K2HPO4, 1 mM NaH2PO4,
11 mM NaHCO3,5 8m MK C l ,5 6m MN a C l ,1m MM g C l 2,
14 mM glucose, 0.02 mM saponin, pH 7.5) followed by intensive
washing. Parasites were disrupted by three cycles of freezing and
thawing and ultrasonication in digestion buffer (4 M urea, 0.4%
Triton X-100, 50 mM Tris-HCl, 5 mM EDTA, 10 mM MgSO4,
pH 8.0) in the presence of protease inhibitors. RNA/DNA-digestion
was performed with benzonaseH (Merck) for 30 min at 4uC. A first
centrifugation step at 15,000 g removed contaminating haemozoin.
The supernatant after centrifugation at 100,000 g for 30 min was
used as ‘‘parasite’’ extract for fractionation. The insoluble pellet was
used as ‘‘insoluble fraction’’ for the analyses.
Protein immunoblotting analysis
The electrophoretic pattern of some proteins was investigated
by immunoblot analysis using specific polyclonal antibodies.
Proteins were resolved by Tris-Tricine-PAGE and were trans-
ferred onto a PVDF membrane. The blots were incubated with
antibodies and washed according to standard procedures. The
following polyclonal antibodies were used: rabbit-anti-PfTrxR,
rabbit-anti-PfGST, rabbit-anti-PfGR (available in the Becker Lab),
rabbit-anti-Histone H3 (Abcam, Cambridge, UK), rabbit-anti-
PfEBP1 (MRA-2 by MR4) at appropriate dilutions 1:1,000–5,000
and peroxidase-conjugated anti-rabbit antibody (Dianova, Ham-
burg, Germany, anti-IgG, 1:50,000–100,000). Vizualisation was
performed by enhanced chemiluminescence (ECL, SuperSignal
West Femto Maximum Sensitivity Substrate (Pierce Biotechnolo-
gy, Rockford, IL, USA). Densitometric quantitation was per-
formed using the Quantity One software (BioRad) by quantitating
band volumina (trace intensity6mm
2) of each sample and
comparing treated and control band volumina.
Proteome subfractionation
To reduce sample complexity (number of protein species/
sample) and to enrich proteins being of ‘‘lower abundance’’ out of
the unfractionated samples, we established a procedure for
subfractionating the Plasmodium falciparum proteome. Before
fractionation, samples to be compared (light and heavy) were
mixed in a protein to protein ratio of 1:1 wt/wt. Weak anion
exchanger chromatography was used to subfractionate the soluble
proteins of P. falciparum. Vivapure Mini H, D ion exchanger
columns (Diethylamine (D). Weak basic anion exchanger (R-CH2-
NH
+-(CH2H5)2, Sartorius, Germany) were loaded with the sample
according to the manufacturer’s instructions. The columns were
equilibrated with a buffer containing 2 M urea, 0.2% Triton,
25 mM Tris, 2.5 mM EDTA, 5 mM MgSO4, pH 8.0 and then
loaded with 1:1 mixed protein extract. Bound proteins were eluted
according to two different procedures. The first procedure
included elution according to pH (buffer containing 2 M urea,
0.2% Triton, 25 mM Tris (or sodium acetate), 2.5 mM EDTA,
5 mM MgSO4, pH 8.0, 7.0, and 3.0. For effective elution each
step was performed with three single column volumina. The
second elution procedure was performed by stepwise increasing
salt concentrations (200–500 mM NaCl). Furthermore a third
procedure for crude sample fractionation was applied by
sequential NH4SO4 precipitation (40%, 70%, and 90% NH4SO4).
Protein concentration in eluted samples was measured, fractions
were precipitated by OrgoSol
TM-DETERGENT-OUT
TM Deter-
gent Removal Kit (Calbiochem, Darmstadt, Germany) and
separated by SDS-PAGE to monitor fractionation or used for
LC-MS analyses.
Multidimensional protein identification technology
(MudPIT)
Precipitated P. falciparum protein preparations were dissolved in
digestion buffer, digested with trypsin and LysC, and analyzed by
LC/LC/MS/MS according to published protocols [22,23].
Approximately 100 mg of protein was used for a 6-step for soluble
samples and 12-step for insoluble LC/LC/MS/MS analysis on a
LTQ-Orbitrap, a hybrid mass spectrometer in which a linear ion
trap is coupled to an Orbitrap mass analyzer (ThermoElectron,
San Jose, CA). All samples were analyzed in triplicate. The
obtained MS/MS spectra were analyzed with SEQUEST 2.7
[24,25] using a non-redundant Plasmodium database (PlasmoDB
version 5.0) [26]. The SEQUEST outputs were analyzed by
DTASelect 2.0 [27]. DTASelect 2.0 uses a quadratic discriminant
analysis to dynamically set XCorr and DeltaCN thresholds for the
entire data set to achieve a user-specified false positive rate (5% in
this analysis). The false positive rates were estimated by the
program from the number and quality of spectral matches to the
decoy database [28].
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After filtering the results from SEQUEST using DTASelect2,
ion chromatograms were generated using an updated version of a
program previously written in our laboratory [29]. This software,
called Census [30], is available from the authors for individual use
(for details, see http://fields.scripps.edu/Census).
Census calculates peptide ion intensity ratios for each pair of
extracted ion chromatograms. The basis of the program is a linear
least-squares correlation that is used to calculate the ratio (i.e.,
slope of the line) and closeness of fit (i.e., correlation coefficient [r])
between the data points of the unlabeled and labeled ion
chromatograms. In this study, only peptide ratios with determi-
nant scores (r2.0.5) were used for further analysis [31].
Peptides were evaluated after first taking the union of search
results (DTASelect2.0 output files) so that a peptide needs only be
identified in one of the replicates to be quantified.
Quantification data of proteins were acquired by calculating a
weighted average of the identified and quantified peptides of the
protein from all fractions. The output from Census is a ratio 1 of
the unlabeled and labeled sample for the drug treated sample
(unlabeled drug treated1/labeled control1) as well as a ratio 2 for
the control sample (unlabeled control2/labeled control2)o fa
different MudPIT run (normalization run). Through calculation of
a ratio of ratios (1/2) for each quantified peptide we filtered out
eventual labeling deficiencies and received a ratio that corresponds
to (unlabeled drug treated/unlabeled control). The changes
observed by Census identify proteins with differential expression
status upon drug treatment.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0004098.s001 (1.69 MB
DOC)
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